title: Treatment of Xanthelasma Palpebrarum With Intralesional Pingyangmycin.
abstract: BACKGROUND
  Xanthelasma palpebrarum (xanthelasma) is the most common type of cutaneous xanthoma, and many patients tend to seek medical treatments for cosmetic reasons. Many methods treating xanthelasma have been proposed, but none of these options can be regarded as a perfect solution.
  
  
  OBJECTIVE
  To study and evaluate the intralesional injection treatment of xanthelasma with pingyangmycin, which has been widely used as a broad-spectrum antitumor antibiotic.
  
  
  METHODS
  21 lesions in 12 patients were treated by intralesional pingyangmycin. Photographs were taken before and after each treatment session. Patients were followed up for 7 to 36 months.
  
  
  RESULTS
  All patients except one received satisfactory results after up to 2 sessions. Only 1 patient had a local recurrence 1 year after the treatment. No severe complications such as infection, atrophy, ulceration, or scar were noticed.
  
  
  CONCLUSIONS
  Intralesional pingyangmycin is a cheap, effective, and safe treatment for xanthelasma, which has been well accepted by patients.
authors.affiliation: *Department of Plastic and Reconstructive Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China; †Department of Orthopedics, PLA 456 Hospital, Jinan, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.forename: Yingshen
authors.initials: Y
authors.lastname: Shi
authors.forename: Huapeng
authors.initials: H
authors.lastname: Guan
authors.forename: Caiyue
authors.initials: C
authors.lastname: Liu
authors.forename: Wenjun
authors.initials: W
authors.lastname: Zhang
authors.forename: Yingfan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Antang
authors.initials: A
authors.lastname: Liu
authors.forename: Yuxin
authors.initials: Y
authors.lastname: Qian
authors.forename: Yaozhong
authors.initials: Y
authors.lastname: Zhao
authors.forename: Hua
authors.initials: H
authors.lastname: Jiang
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005141:Eyelid Diseases / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D010781:Photography; D012008:Recurrence; D012871:Skin Diseases / Q000188:drug therapy*; D016896:Treatment Outcome; D014973:Xanthomatosis / Q000188:drug therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; C025703:bleomycetin